Targeting HIF-1α by newly synthesized Indolephenoxyacetamide (IPA) analogs to induce anti-angiogenesis-mediated solid tumor suppression.

BACKGROUND: Hypoxic microenvironment is a common feature of solid tumors, which leads to the promotion of cancer. The transcription factor, HIF-1α, expressed under hypoxic conditions stimulates tumor angiogenesis, favoring HIF-1α as a promising anticancer agent. On the other hand, synthetic Indolephenoxyacetamide derivatives are known for their pharmacological potentiality. With this background here, we have synthesized, characterized, and validated the new IPA (8a-n) analogs for anti-tumor activity. METHODS: The new series of IPA (8a-n) were synthesized through a multi-step reaction sequence and characterized based on the different spectroscopic analysis FT-IR, 1H, 13C NMR, mass spectra, and elemental analyses. Cell-based screening of IPA (8a-n) was assessed by MTT assay. Anti-angiogenic efficacy of IPA (8k) validated through CAM, Rat corneal, tube formation and migration assay. The underlying molecular mechanism is validated through zymogram and IB studies. The in vivo anti-tumor activity was measured in the DLA solid tumor model. RESULTS: Screening for anti-proliferative studies inferred, IPA (8k) is a lead molecule with an IC50 value of ˜5 µM. Anti-angiogenic assays revealed the angiopreventive activity through inhibition of HIF-1α and modulation downstream regulatory genes, VEGF, MMPs, and P53. The results are confirmative in an in vivo solid tumor model. CONCLUSION: The IPA (8k) is a potent anti-proliferative molecule with anti-angiogenic activity and specifically targets HIF1α, thereby modulates its downstream regulatory genes both in vitro and in vivo. The study provides scope for new target-specific drug development against HIF-1α for the treatment of solid tumors.

A systems biology approach to identify the key targets of curcumin and capsaicin that downregulate pro-inflammatory pathways in human monocytes.

VEGFR1 (Flt-1), is a high-affinity tyrosine kinase receptor of VEGF found primarily on vascular endothelial cells. Recently, Flt-1 has shown to be expressed in human monocytes. However, the key intracellular signaling pathway mediated by Flt-1 receptor has been yet to be identified in monocytes. In this regard, using a robust systems biology approach, the key druggable target(s) involved in inflammatory angiogenesis mediated through VEGFR1 signaling was identified. Furthermore, experimental validation of key drug targets is conducted using PMA- and VEGF- stimulated human monocyte THP-1 cell lines. The key network pathways and corresponding disease modules were analyzed to identify the important biological processes perturbed in diseases. Using topological analysis, ICAM1 was identified as putative regulator of monocytes migration into tumor-micro environment. And these targets were examined by treating with curcumin and capsaicin molecules. Our results showed that these two molecules inhibited the over expression of targets such as ICAM1, Flt-1, and NF-κB in the VEGFR1 signalling pathway by reducing THP-1 chemotaxis. Besides, Curcumin and Capsaicin down-regulated expression of pro-inflammatory cytokines TNF-α, IL-6, and CXCL8/IL-8 and up regulated the expression of IL-10, a sign of lowered M1/M2 ratio relating to abrogation of inflammation.

The anti-invasive role of novel synthesized pyridazine hydrazide appended phenoxy acetic acid against neoplastic development targeting matrix metallo proteases.

Neoplastic metastasis is a major process where tumor cells migrate from the primary tumor and colonize at other parts of our body to form secondary tumor. Cancer incidences are rising and novel anti-neoplastic compounds with new mechanism of actions are essential for preventing cancer related deaths. In the current examination, a novel series of pyridazine analogues 6a-l was synthesized and evaluated against metastatic neoplastic cells. Experimental data postulated compound 6j has potential cytotoxic efficacy with prolonged activity against various cancer cells, including A549, HepG2, A498, CaSki and SiHa cells. Moreover, compound 6j arrests the A549 migration and invasions markedly by counteracting matrix metalloproteinase (MMP)-2 and MMP-9 expressions. Also, compound 6j proved its potentiality against Dalton's solid lymphoma progression in-vivo by abridging MVD and MMP expressions. Compound 6j interacts with MMP-2 and MMP-9 by H- bond in-silico, thereby down regulates the MMPs action in tumourigenesis. Altogether, we concluded that compound 6j down regulates MMP-2 and MMP-9 and thereby impairs metastatic cancer cell migration and invasions which can be translated into a potent anti-neoplastic agent.